Piritrexim, a lipid-soluble antifolate, was evaluated for its activity against Pneumocystis carinii and Toxoplasma gondii. The concentration of piritrexim needed to inhibit 50% of the catalytic activity of P. carinii dihydrofolate reductase (DHFR) was 19.3 nM, and that for T. gondi DHFR was 17.0 nM, concentrations that were 40-to over 1,000-fold less than those needed for the inhibition of activity by trimethoprim and pyrimethamine, the antifolates conventionally used in treating these organisms. Piritrexim was able to inhibit replication of T. gondii in a mouse peritoneal macrophage model at concentrations of 0.1 to 1.0 ILM.
Pneumocystis carinii and Toxoplasma gondii are major causes of morbidity and mortality in patients with the acquired immunodeficiency syndrome (AIDS), as well as in patients with other immunosuppressive disorders (7, 9, 13, 16) . The only regimens with documented efficacy for the treatment of these infections are pentamidine, trimethoprimdapsone, and trimethoprim-sulfamethoxazole for P. carinji and pyrimethamine plus a sulfonamide for T. gondii (10, 12, 15, 17) . Adverse reactions associated with these regimens occur frequently, especially in patients with AIDS, and often necessitate termination of therapy. New (8) .
Piritrexim (BW301) is a lipid-soluble analog of methotrexate that differs from trimetrexate primarily because it is a dimethoxy rather than a trimethoxy analog and has a shorter bridging link between the two ring structures (Fig. 1) . The structures of trimetrexate and piritrexim more closely resemble folates than do the diaminopyrimidines trimethoprim and pyrimethamine (Fig. 1) . Piritrexim tinin, 100 gjg/ml; phenylmethylsulfonyl fluoride, 5 ,ug/ml). Phenylmethylsulfonyl fluoride was obtained from Boehringer-Mannheim Biochemicals (Indianapolis, Ind.). The other inhibitors were obtained from Sigma Chemical Co. (St. Louis, Mo.). The supernatant obtained following centrifugation at 27,000 x g was used in enzyme assays.
The RH strain of T. gondii was passaged every 3 to 4 days by intraperitoneal inoculation of BALB/c mice. For enzyme inhibition or in vitro replication inhibition studies, T. gondii was harvested by peritoneal lavage 4 days after inoculation. Organisms were partially purified by differential centrifugation as described previously (3) . For enzyme studies, organisms were sonicated in the presence of protease inhibitors and processed as described above for P. carinii.
DHFR catalytic assay. DHFR catalytic activity was measured by using a standard spectrophotometric assay (5) . The standard reaction mixture contained 0.1 mM NADPH, 160 mM Tris hydrochloride (pH 7.2), and 160 mM KCl and various concentrations of inhibitors in a final volume of 0.5 ml. The reaction was initiated after equilibration at 37°C by the addition of 50 nmol of dihydrofolate. The reaction velocity was measured by the disappearance of NADPH at 340 nM. Results from the catalytic assay were calculated by using ALLFIT, a least-squares curve-fitting program capable of simultaneous curve-fitting (6) . The standard error of the mean was calculated by determining the average concentration that inhibited 50% of the catalytic activity in at least four individual experiments.
T. gondii replication inhibition. For replication inhibition studies, fresh peritoneal macrophages were harvested from BALB/c mice by peritoneal lavage, suspended at 106 cells per ml, and cultured (1 ml per well) in two chambered sterile slides (Lab-tek; Miles Laboratories, Inc., Naperville, Ill.) for 24 h in RPMI 1640 medium supplemented with 10% fetal bovine serum-100 U of penicillin per ml-100 ,g of streptomycin per ml (8) . Tissue culture media and additives were obtained from MA Bioproducts (Walkersville, Md.). Cells were then infected with 1 ml of T. gondii (2 x 106 tachyzoites per ml) for 1 h, washed 5 times, and incubated for 18 h in RPMI 1640 medium supplemented as described above or supplemented with inhibitors. For synergy studies, RPMI 1640 medium was replaced with RPMI 1640 medium without folic acid or para-amino benzoic acid, as described previ- methoprim and pyrimethamine in inhibiting the DHFRs from these organisms. Piritrexim was also effective in inhibiting the in vitro replication of T. gondii in mouse peritoneal macrophages. Almost total inhibition of relication was seen at 1 ,uM, and partial inhibition was seen at 100 nM ( Table 2 ). These concentrations were somewhat greater than those needed with trimetrexate, but were approximately 10-fold less than the concentration of pyrimethamine needed to inhibit replication.
Leucovorin at equimolar to 100-fold higher concentrations than piritrexim had no effect on the ability of piritrexim to inhibit the replication of T. gondii (data not shown). Sulfadiazine alone at concentrations of 200 ,ug/ml was not able to inhibit the replication of T. gondii. However, when this concentration of sulfadiazine was combined with subtherapeutic concentrations of piritrexim, the combination was more effective in inhibiting T. gondii replication than was either drug alone (Table 3) .
DISCUSSION
The increased incidence of P. carinii and T. gondii disease in immunocompromised patients, especially patients with AIDS, combined with the limited number of well-tolerated therapeutic regimens, has prompted a search for more effective, safer, alternative regimens. Recently, trimetrexate, a lipid-soluble analog of methotrexate, has been found (2, 3, 8) to be a very potent inhibitor of P. carinii and T. gondii DHFRs in vitro, as well as a potent inhibitor of T. gondii replication in cultured peritoneal macrophages. Results of preliminary clinical trials with trimetrexate have suggested that it is a potent agent alone or combined with a sulfonamide in the treatment of AIDS patients with P. carinii pneumonia (1) .
Piritrexim (BW301) is a lipid-soluble analog of methotrexate that is structurally similar to trimetrexate, but that has different pharmacokinetic properties in humans, including a shorter half-life (4.5 h for piritrexim versus 9 to 16 h for trimetrexate) ( Only clinical studies will be able to determine whether the structural differences or altered metabolism of piritrexim is associated with increased efficacy or decreased toxicity when used in this manner.
The addition of a sulfonamide to a DHFR inhibitor appears to result in improved therapeutic efficacy. In this study, sulfadiazine, which alone was not effective in inhibiting the replication of T. gondii, acted synergistically with piritrexim in inhibiting T. gondii replication (Table 3) . Similar results have been found with trimetrexate (8) . Although patients with AIDS have a high incidence of adverse reactions to sulfonamides, it is possible that a more effective DHFR inhibitor than trimethoprim or pyrimethamine, such as piritrexim, could be combined with lower doses of sulfonamides than are currently being used clinically to minimize toxicity without losing efficacy. Further studies are needed to determine whether structural analogs of methotrexate, such as piritrexim, alone or combined with a sulfonamide, will be more effective or less toxic than the current regimens used to treat P. carinii and T. gondii disease.
